| Literature DB >> 26063982 |
Jie Ma1, Chuanxi Chen1, Andreas S Barth2, Chris Cheadle3, Xiangdong Guan4, Li Gao3.
Abstract
BACKGROUND: Sepsis is a leading cause of mortality in intensive care units worldwide. A better understanding of the blood systems response to sepsis should expedite the identification of biomarkers for early diagnosis and therapeutic interventions.Entities:
Mesh:
Year: 2015 PMID: 26063982 PMCID: PMC4430672 DOI: 10.1155/2015/984825
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Selection of existing GEO series. A total of 25 GEO series in human were obtained using the key word “sepsis” and only 9 series met the criteria. We included 6 out of 9 series, which used whole blood samples, 3 series which used other tissue types (PBMC, muscle, and HMVEC) were excluded.
Figure 3Lysosome and cytoskeleton pathways are enriched across multiple studies in blood of septic patients. This figure displays the −log P values (with P < 0.05 as cut-off) yielded from Student's t-test for the mean of average expression of genes in each pathway, comparing sepsis patients to the controls in each dataset, and only significantly up-regulated genes with either P value <0.01 or FDR >1.5 were included in the analysis.
Figure 5Graphical representations of protein interactions enriched for mortality phenotype. We queried the Unified Human Interactome database (UniHI 7) [21] with a list of top 15 transcripts from each of the two pathways. The display was restricted to those interactions (yellow proteins) supported by at least three PubMed references. Molecular network analysis revealed that 22 out of 30 transcripts formed a network with multiple interconnected nodes (hubs) between top genes in both pathways. Importantly, many of the predicted interaction partners (red proteins), including 3 query proteins (MAPK1, CTSA, and NEU1), were associated with the mortality phenotype.
Figure 2Top 10 up- and downregulated KEGG pathways in human sepsis. KEGG pathways were sorted ascending for upregulation and descending for downregulation by net expression and visualized in Genesis software. Here we only showed top ten pathways that had either the highest or the lowest net expression in each individual study. Blue color represents negative net expression and red color means positive net expression. The absolute net expression value is proportionate with color brightness, the brighter the color the higher the absolute value.
Whole blood transcriptional profiles identified top up- and downregulated pathways in human sepsis.
| Upregulated pathways | Rank scores∗ | Downregulated pathways | Rank scores∗ |
|---|---|---|---|
| Lysosome | 47 | Ribosome | 69 |
| Regulation of actin cytoskeleton | 46 | Spliceosome | 55 |
| Pathways in cancer | 45 | Antigen processing and presentation | 35 |
| MAPK signaling pathway | 34 | Cell adhesion molecules | 34 |
| Fc gamma R-mediated phagocytosis | 26 | Intestinal immune network for IgA production | 31 |
| Chemokine signaling pathway | 23 | Graft-versus-host disease | 28 |
| Toll-like receptor signaling | 17 | Purine metabolism | 21 |
| Neurotrophin signaling pathway | 16 | Autoimmune thyroid disease | 15 |
| Insulin signaling pathway | 16 | Allograft rejection | 14 |
| Focal adhesion | 14 | T cell receptor signaling pathway | 13 |
| Leukocyte transendothelial migration | 12 | Cytokine-cytokine receptor interaction | 9 |
| Alzheimer's disease | 12 | Primary immunodeficiency | 8 |
| Endocytosis | 8 | Natural killer cell mediated cytotoxicity | 8 |
| Olfactory transduction | 8 | Viral myocarditis | 7 |
| Cell cycle | 7 | Hematopoietic cell lineage | 7 |
| Renal cell carcinoma | 6 | RIG-I-like receptor signaling pathway | 7 |
| Oocyte meiosis | 6 | RNA degradation | 6 |
| Chronic myeloid leukemia | 5 | Jak-STAT signaling pathway | 6 |
| Complement and coagulation cascades | 5 | Type I diabetes melitus | 4 |
| Oxidative phosphorylation | 4 | Phosohatidylinositol signaling system | 4 |
| Fc epsilon RI signaling pathway | 2 | ||
| Inositol phosphate metabolism | 1 |
∗Pathways were listed according to rank scores (from high to low). Rank scores were given to the top 10 up- or downregulated KEGG pathways in each study (with rank scores assigned from 1 to 10, 10 represented the most significant pathway) and a top KEGG pathway was defined if it had the highest combined rank scores and most appearances across all studies.
Figure 4Target molecules in lysosome pathway dysregulated in human sepsis. Lysosome is a cytoplasmic organelle containing enzymes that break down biological polymers. Organization of the lysosome is depicted as dense spherical vacuole containing a variety of acid hydrolases (close circle: proteases; open circle: galactosidase; open triangle: sulfatase) that are active at the acidic pH maintained within the lysosome. Furthermore, both the major (double rectangle boxes in grey) and minor (double rectangle boxes) lysosomal membrane proteins are involved. ATPase (H+ transporting) is displayed as open rectangle and “other lysosomal enzymes and activities” are displayed as close star.
| GEO accession | Comparison groups | Probe ID | Publication (PMID) |
|---|---|---|---|
| GSE30119 | Healthy ( | 48802 | 22496797 |
|
| |||
| GSE8121 | Nonseptic ( | 54675 | 17932561 |
|
| |||
| GSE9692 | Normal ( | 54675 | 18460642 |
|
| |||
| GSE28750 | Healthy ( | 54675 | 21682927 |
|
| |||
| GSE13015∗ | Platform6106: nonsepsis ( | 48687 | 19903332 |
| Platform6947: nonsepsis ( | 48803 | 19903332 | |
|
| |||
| GSE21802 | Healthy ( | 48701 | 20840779 |
| GEO accession | Patients characteristics | Source of infection | Time of data collection |
|---|---|---|---|
| GSE30119 | Age >10 and <18 year-old | Blood and marrow or arthritis ( | Different days during hospitalization |
|
| |||
| GSE8121 | Age <10 year-old | Blood (15) | (1) Within 24 h of admission to ICU (day 1) |
|
| |||
| GSE9692 | Age <10 year-old | Blood (10) | Within 24 h of admission to ICU |
|
| |||
| GSE28750 | Age >18 year-old | All blood | Septic patients: within 24 h of admission |
|
| |||
| GSE13015∗ | Age >18 year-old | All blood | Within 7 days of diagnose |
|
| |||
| GSE21802 | Age >18 and <65 year-old | Lung ( | Early period (before day 9 in the course of the disease) |
∗GSE13015 was a published study using 2 different microarray platforms and in different patients, therefore was considered as two separate studies in the statistical analysis.
(a) Lysosome pathway
| Gene Symbol | Gene Name | #1 | #2 | #3 | #4 | #5 | #6 | #7 | PubMatrix∗ |
|---|---|---|---|---|---|---|---|---|---|
|
| Sortilin 1 | 2.16 (13) | 4.05 (9.8) | 4.48 (10.5) | 5.19 (8.4) | 4.86 (4.4) | 7.82 (2.3) | — | 0 |
|
| Cathepsin D | 1.86 (10.9) | 2.57 (7) | 2.36 (6) | 2.1 (8) | 2.75 (8.8) | — | 5.94 (5.9) | 3 |
|
| Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 | 3.69 (5.6) | 2.62 (6.5) | 3.98 (8.4) | 2.4 (5) | 3.31 (5.3) | 3.85 (4.7) | — | 4 |
|
| CD63 molecule | 2.02 (5.9) | 3.35 (8.4) | 3 (10.5) | 2.84 (8.7) | 2.82 (6.1) | — | — | 38 |
|
| Glucosamine (N-acetyl)-6-sulfatase | — | 3.17 (5.9) | 3.91 (8.3) | 2.76 (6.3) | 1.85 (5.8) | — | 2.77 (4.4) | 10 |
|
| GM2 ganglioside activator | — | 1.85 (4.2) | 2.55 (6.5) | 2.42 (7.6) | 3.11 (5) | 6.17 (3.7) | — | 0 |
|
| Lysosomal-associated membrane protein 2 | — | — | 1.79 (2.2) | 1.63 (3.7) | 1.56 (6) | 2.02 (3.9) | 3.66 (2.7) | 6 |
|
| Lysosomal protein transmembrane 4 beta | 1.76 (7) | — | 1.54 (3.4) | 1.82 (2) | 2.31 (3.3) | 2.07 (3.8) | — | 0 |
|
| Cathepsin A | 1.98 (13.6) | 2.13 (5.3) | 2.26 (4.8) | 1.81 (4.3) | — | — | — | 4 |
|
| galactosidase, alpha | — | 1.63 (5.2) | 1.65 (4.3) | 1.52 (7.4) | 1.68 (6.5) | — | 1.59 (2.6) | 95 |
|
| sialidase 1 (lysosomal sialidase) | — | 1.67 (4.1) | 1.65 (3.6) | — | 1.87 (9.3) | — | 1.93 (2.1) | 0 |
|
| cathepsin B | — | 2.41 (6.2) | 2.05 (4) | — | — | 1.84 (5.1) | 1.78 (3.3) | 2 |
|
| ATPase, H+ transporting, lysosomal accessory protein 1 | — | — | 1.59 (3.8) | — | 1.67 (4.4) | 2.12 (4.3) | 1.57 (4.1) | 0 |
|
| lysosomal-associated membrane protein 1 | — | 1.55 (2.1) | 1.62 (3.2) | — | — | 1.68 (5.3) | — | 4 |
|
| adaptor-related protein complex 3, beta 2 subunit | — | — | 1.6 (2.1) | 2.32 (4.6) | 266.89 (3.8) | — | — | 0 |
(b) Cytoskeleton pathway
| Gene Symbol | Gene Name | #1 | #2 | #3 | #4 | #5 | #6 | #7 | PubMatrix∗ |
|---|---|---|---|---|---|---|---|---|---|
|
| integrin, alpha M (complement component 3 receptor 3 subunit) | 1.72 (7.98) | 2.82 (6.41) | 2.88 (9.42) | 3.19 (8.44) | 3.16 (9.19) | 4.36 (6.19) | 4.01 (3.99) | 356 |
|
| LIM domain kinase 2 | 1.69 (3.39) | 2.83 (5.24) | 4.3 (9.27) | 2.08 (4.79) | 5.72 (8.34) | 11.72 (4.1) | — | 0 |
|
| platelet derived growth factor C | 1.9 (9.1) | 2.55 (2.75) | 2.63 (3.84) | 6.04 (5.54) | 2.86 (3.22) | 7.74 (3.45) | — | 0 |
|
| phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta | — | 1.96 (3.54) | 2.8 (6.61) | 2.57 (6.07) | 2.08 (8.43) | 3.55 (3.7) | 2.99 (3.7) | 3 |
|
| son of sevenless homolog 2 (Drosophila) | 1.58 (4.52) | 2.32 (4.43) | 2.66 (5.3) | 2.41 (4.77) | 2.67 (7.69) | 3.57 (3.7) | — | 0 |
|
| gelsolin | 1.87 (10.35) | 2.09 (4.28) | 1.63 (3.04) | 1.59 (2.47) | 2.09 (4.99) | 2.93 (3.74) | — | 2 |
|
| slingshot homolog 1 | 1.67 (4.24) | 2.17 (4.97) | 2.12 (4.54) | 1.68 (3.17) | 1.69 (2.17) | 4.85 (2.4) | — | 0 |
|
| fibroblast growth factor 13 | — | 3.6 (3.81) | 4.87 (5.35) | 6.27 (10.06) | 12.36 (4.07) | 105.9 (2.54) | — | 0 |
|
| diaphanous homolog 2 | — | 1.65 (2.4) | 2.23 (6.84) | 2.47 (7.12) | 2.08 (4.64) | 2.71 (2.21) | — | 0 |
|
| p21 (CDKN1A)-activated kinase 2 | — | 1.76 (4.62) | 1.82 (5.18) | — | 1.88 (9.03) | 1.70 (3.78) | 1.84 (2.27) | 0 |
|
| CD14 molecule | 1.54 (5.97) | 2.51 (4.48) | 2.33 (3.18) | — | 1.54 (2.56) | 1.77 (2) | — | 1564 |
|
| integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | 3.09 (9.06) | 1.74 (2.6) | — | 4.42 (4.9) | — | 3.44 (3.84) | — | 0 |
|
| B-Raf proto-oncogene, serine/threonine kinase | — | 1.94 (3.7) | 2.2 (9.68) | 2.68 (8.92) | — | 1.90 (2.04) | — | 2 |
|
| myosin, light chain 9, regulatory | 3.39 (10.79) | — | — | 3.38 (3.84) | 2.25 (2.45) | 2.53 (2.01) | — | 0 |
|
| mitogen-activated protein kinase 1 | — | 2 (7.85) | 1.85 (2.74) | 1.79 (6.61) | — | 1.89 (4.94) | — | 137 |
GEO series #1 to 7 are listed: GSE30119, GSE8121, GSE9692, GSE28750, GSE13015-6106, GSE13015-6947 and GSE21802.
∗Number of publications associated with search terms “sepsis”, “severe sepsis” or “septic shock” in PubMed by searching the PubMatrix database.